BiotechTube

Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX

Phase 2/3Recruiting
0 views this week 0 watching⚡ Active
Interest: 45/100
45
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Untreated, Unresectable, or Metastatic Colorectal Cancer

Conditions

Untreated, Unresectable, or Metastatic Colorectal Cancer

Trial Timeline

Dec 31, 2025 → Mar 11, 2034

NCT ID
NCT07221357

About Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX

Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX is a phase 2/3 stage product being developed by Bristol Myers Squibb for Untreated, Unresectable, or Metastatic Colorectal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07221357. Target conditions include Untreated, Unresectable, or Metastatic Colorectal Cancer.

What happened to similar drugs?

1 of 4 similar drugs in Untreated, Unresectable, or Metastatic Colorectal Cancer were approved

Approved (1) Terminated (1) Active (2)
✅Nivolumab + RelatlimabBristol Myers SquibbApproved
🔄Acalabrutinib + Rituximab + ChlorambucilAstraZenecaPhase 3
🔄Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3
❌Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
15
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07221357Phase 2/3Recruiting

Competing Products

15 competing products in Untreated, Unresectable, or Metastatic Colorectal Cancer

See all competitors
ProductCompanyStageHype Score
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusionAbbViePhase 2
35
Onureg + VenetoclaxAbbViePhase 1/2
36
Acalabrutinib + Rituximab + ChlorambucilAstraZenecaPhase 3
44
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatinAstraZenecaPhase 2
27
Surovatamig + R-CHOP + R-CVP + BRAstraZenecaPhase 3
47
MK-3475 + Lenvatinib + Carboplatin + PaclitaxelMerckPhase 2
42
UFOX + Cetuximab + FOLFOX4 + CetuximabMerckPhase 2
35
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + VincristineRochePhase 2
35
Rituximab + ACVBP regimen plus PegfilgrastimAmgenPhase 2
35
Idelalisib + Nab-paclitaxel + mFOLFOX6Gilead SciencesPhase 1
21
PF-08634404 + Chemotherapy + NivolumabPfizerPhase 2/3
45
Nivolumab + RelatlimabBristol Myers SquibbApproved
50
Lenalidomide + Dexamethasone + ElotuzumabBristol Myers SquibbPhase 3
32
Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + GemcitabineBristol Myers SquibbPhase 2
35
Pumitamig + Folfox + Capox + NivolumabBristol Myers SquibbPhase 2/3
45